#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Dementia Alzheimer's type Colorectal cancer Ovarian cancer Hepatocellular carcinoma Dermatitis atopic Breast cancer metastatic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Myotonia Anti-myelin-associated glycoprotein antibodies positive Depression Postprandial hypoglycaemia Malignant oligodendroglioma Thrombotic microangiopathy Cerebral arteriovenous malformation haemorrhagic Toxic epidermal necrolysis Medullary thyroid cancer Noonan syndrome Rheumatoid arthritis Primary immunodeficiency syndrome Squamous cell carcinoma of head and neck Gastroenteropancreatic neuroendocrine tumour disease Small intestine neuroendocrine tumour More trials…

    Learn about Rare Diseases

    Nephrotic syndrome Angiosarcoma recurrent – Life with Disease Waldenstrom’s macroglobulinaemia recurrent – Basic Information Breast angiosarcoma metastatic – Trials in Disease Pleural mesothelioma malignant Pulmonary fibrosis – Diagnostics Retinitis pigmentosa Activated PI3 kinase delta syndrome – Treatment Congenital hypotransferrinaemia – Diagnostics Glomerulonephritis rapidly progressive – Life with Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Cefiderocol UDONITRECTAG GSK5458514 Amitriptyline Relacorilant METHYLPHENIDATE Burfiralimab Ontasameran OLVEREMBATINIB Voriconazole Aliskiren Doxylamine Hydrogen Succinate Safinamide Ly4100511 Tiotropium Bromide Tremelimumab Alpha-Tocopherol SEVUPARIN Sarilumab Onasemnogene Abeparvovec More therapies…

    Learn about Your Condition

    Lymphangiosarcoma Bronchiolitis Triple positive breast cancer Acute coronary syndrome Atrial flutter Ischaemic skin ulcer Diabetic gastroparesis Epicondylitis B-cell lymphoma refractory Behavioural addiction Giardiasis Diphtheria Ebola disease Delirium Burkitt's lymphoma More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Luxembourg

  • Study Comparing Datopotamab Deruxtecan and Docetaxel for Patients with Advanced or Metastatic Non-Small Cell Lung Cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Non-small cell lung cancer
    Investigated Drugs:
    • Datopotamab Deruxtecan
    • Docetaxel
    Belgium France Germany Italy The Netherlands Poland +1

  • Study on the Safety and Effectiveness of IMGN151 for Women with Recurrent Endometrial and Ovarian Cancer

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Cervix carcinoma recurrent
    • Malignant peritoneal neoplasm
    • Ovarian epithelial cancer
    Investigated Drugs:
    • Imgn151
    • Prednisolone Acetate
    • Brimonidine Tartrate
    Belgium France Germany Ireland Italy The Netherlands +1

  • Study on Durvalumab, Paclitaxel, Carboplatin, and Olaparib for Patients with Advanced or Recurrent Endometrial Cancer

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Durvalumab
    • Infliximab
    • Mycophenolate Mofetil
    Belgium Estonia Germany Greece Hungary Lithuania +2

  • Study on the Effects and Safety of Camizestrant (AZD9833) Compared to Fulvestrant in Postmenopausal Women with Advanced ER-Positive HER2-Negative Breast Cancer

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Breast cancer
    Investigated Drugs:
    • Camizestrant
    • Fulvestrant
    Belgium France Hungary Italy Poland Portugal +1

  • Study on DF1001, Nivolumab, and Paclitaxel for Patients with Advanced Solid Tumors

    Not recruiting

    1 1 1 1
    Investigated Diseases:
    • Neoplasm
    Investigated Drugs:
    • Df1001
    • Nivolumab
    • Paclitaxel Albumin-Bound
    Belgium Denmark France The Netherlands

  • Study of SBP-101, Nab-Paclitaxel, and Gemcitabine for Patients with Metastatic Pancreatic Cancer

    Not recruiting

    4 1 1
    Investigated Diseases:
    • Ductal adenocarcinoma of pancreas
    Investigated Drugs:
    • Ivospemin
    • Gemcitabine
    • Paclitaxel Albumin-Bound
    Austria Belgium France Germany Italy Spain
Previous Page
1 2 3 4 5 6
Next Page

Find Clinical Trials in Your Selected Region and City

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Fluorouracil Folinic Acid Docetaxel Carboplatin Paclitaxel Capecitabine Oxaliplatin Sodium Chloride Pembrolizumab Prednisolone Acetate Fulvestrant Durvalumab Acetylsalicylic Acid Nivolumab Bevacizumab Prednisone Datopotamab Deruxtecan Olaparib Dexamethasone Prasinezumab Paclitaxel Albumin-Bound Sodium Hydrogen Carbonate Pheur Mps-215 Igg4 Tetravalent Bispecific Antibody-Like Protein Against Pd-1 And Ctla4 Clopidogrel Topotecan Trastuzumab Df1001 Mps-216 Saruparib Show more

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

Acute coronary syndrome Adenocarcinoma gastric Bladder transitional cell carcinoma Breast cancer Breast cancer metastatic Breast cancer stage IV Cervix carcinoma recurrent Chronic coronary syndrome Colon cancer stage II Colon cancer stage III Colorectal cancer metastatic Ductal adenocarcinoma of pancreas Embolism Endometrial cancer Endometrial cancer recurrent Fallopian tube cancer Gastric cancer Hormone receptor positive breast cancer Hormone receptor positive HER2 negative breast cancer Hormone-refractory prostate cancer Lung disorder Malignant peritoneal neoplasm Neoplasm Non-small cell lung cancer Oesophageal adenocarcinoma Oesophageal carcinoma Ovarian cancer Ovarian cancer recurrent Ovarian epithelial cancer Parkinson's disease Prostate cancer Radius fracture Rectal cancer stage II Rectal cancer stage III Small cell lung cancer extensive stage

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!